SMDG publishes Nature Index perspective on rare disease drug delivery

S. M. Discovery Group says an invited Nature Index perspective argues that better drug delivery, not just better disease biology, will determine whether children with rare diseases get effective therapies. The piece outlines nanotechnology and non-viral delivery as a path to safer, more scalable precision medicines and calls for a pediatric accelerator.

Why it matters: - Children with rare diseases often still lack disease-modifying treatments, even as genomics and precision diagnostics improve. - The Nature Index perspective argues that delivery technology is now a central bottleneck in turning scientific discoveries into therapies that are safe, scalable and accessible. - The debate affects neurological rare diseases in particular, where getting therapies into the central nervous system remains difficult.

What happened: - S. M. Discovery Group announced the publication of an invited scientific perspective in Nature Index on July 30, 2026. - The article, “To help children with rare diseases, we must solve drug delivery,” was written by Dr. Shadi Farhangrazi, SMDG’s co-founder and CEO, and Professor Moein Moghimi, co-founder of SMDG. - The perspective examines how nanotechnology, engineering biology and non-viral delivery systems could expand treatment options for children with rare diseases. - The paper is available here: the Nature article.

The details: - The authors say future therapies must do more than identify biological targets. - The perspective highlights the need for delivery systems that improve precision, safety, manufacturability and patient access. - Viral vectors and lipid nanoparticle systems have enabled progress in genetic medicine, but the authors point to continuing challenges. - Those challenges include tissue specificity, immune responses, repeat dosing, manufacturing complexity, scalability and affordability. - The authors propose continued scientific innovation, sustained investment and complementary next-generation delivery technologies. - The perspective also calls for a “pediatric accelerator” to support, finance and develop new therapeutics for rare neurological pediatric diseases. - SMDG says its NanoLigand Carriers™ platform could deliver therapies to the right cells in the brain, improve safety, simplify manufacturing and reduce development costs. - The company said it is developing next-generation precision therapeutics for neurological, inflammatory and other complex diseases using proprietary platform technologies.

Between the lines: - The perspective reflects a broader shift in rare disease medicine from discovery to delivery. - That shift matters because a therapy can only help patients if it can be manufactured, administered repeatedly when needed and reach the intended tissue. - The joint authorship pairs scientific credibility in nanomedicine with SMDG’s commercial platform strategy. - Professor Moghimi’s background in targeted drug delivery and nanomedicine reinforces the paper’s emphasis on translation, not just theory. - Dr. Farhangrazi said scientific discovery has transformed understanding of rare pediatric neurological diseases, but the next challenge is turning that knowledge into therapies that are precise, safe, scalable and accessible. - Professor Moghimi said tomorrow’s medicines should be designed for efficacy, precision, safety, manufacturability and accessibility.

What's next: - SMDG is positioning its NanoLigand platform and engineering biology approach as part of the next wave of precision medicine development. - The company says the publication supports its mission of developing tomorrow’s medicines through proprietary platform technologies. - Media interviews with Dr. Farhangrazi and Professor Moghimi are available upon request. - SMDG lists its website as www.smdiscovery.com and its LinkedIn page at S. M. Discovery Group.

The bottom line: - The message from the perspective is straightforward: for many rare pediatric diseases, the next breakthrough may depend less on identifying a target and more on solving how to deliver the therapy.